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Abstract
Background: Several clinical trials have demonstrated the efficacy of fluconazole as empiric
antifungal therapy in cancer patients with fever and neutropenia. Our objective was to assess the
frequency and resource utilization associated with treatment failure in cancer patients given
empiric fluconazole antifungal therapy in routine inpatient care.
Methods: We performed a retrospective cohort study of cancer patients treated with oral or
intravenous fluconazole between 7/97 and 6/01 in a tertiary care hospital. The final study cohort
included cancer patients with neutropenia (an absolute neutrophil count below 500 cells/mm3) and
fever (a temperature above 38°C or 100.4°F), who were receiving at least 96 hours of parenteral
antibacterial therapy prior to initiating fluconazole. Patients' responses to empiric therapy were
assessed by reviewing patient charts.
Results:  Among 103 cancer admissions with fever and neutropenia, treatment failure after
initiating empiric fluconazole antifungal therapy occurred in 41% (95% confidence interval (CI) 31%
– 50%) of admissions. Patients with a diagnosis of hematological malignancy had increased risk of
treatment failure (OR = 4.6, 95% CI 1.5 – 14.8). When treatment failure occurred the mean
adjusted increases in length of stay and total costs were 7.4 days (95% CI 3.3 – 11.5) and $18,925
(95% CI 3,289 – 34,563), respectively.
Conclusion: Treatment failure occurred in more than one-third of neutropenic cancer patients
on fluconazole as empiric antifungal treatment for fever in routine clinical treatment. The increase
in costs when treatment failure occurs is substantial.
Background
Immunocompromised patients are at risk of contracting
serious fungal infections which cause significant morbid-
ity and mortality [1-3]. The diagnosis of fungal infection
in immunocompromised cancer patients is difficult for
the clinician while the risk of fungal infection is high in
patients with prolonged fever and neutropenia who do
not receive antifungal therapy [4,5]. Empiric antifungal
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therapy for patients being treated with broad-spectrum
antibiotics who have prolonged fever and neutropenia
has been demonstrated to be efficacious, and it has
become the standard of practice [5-7]. Newer antifungal
agents have used for empiric antifungal therapy included
liposomal amphotericin B [8] and caspofungin [9].
Fluconazole is active against the major fungal pathogens
(except for mould) in neutropenic cancer patients
although conventional amphotericin B is commonly used
as a first-line agent for documented infections. Clinical tri-
als have shown that fluconazole is an equally effective but
less toxic alternative to amphotericin B for empiric anti-
fungal therapy in cancer patients with prolonged fever
and neutropenia [10-13]. These trials also evaluated clin-
ical response to empiric antifungal therapy and found no
significant difference in treatment failure with the rates of
25%–44% in fluconazole group compared to 33%–54%
in patients on amphotericin B [10,11,13]. The relation-
ships between treatment failure from empiric antifungal
therapy and patient characteristics have been explored in
a trial [11], although economic outcomes were not
reported.
Relatively little information has been available regarding
the frequency and resource use of treatment failure using
fluconazole as empiric antifungal agent in cancer patients
with fever and neutropenia in routine hospital inpatient
care. To address these issues, we performed a retrospective
cohort study with the goals of: 1) characterizing the pat-
terns of care for cancer patients treated empirically with
fluconazole; 2) identifying the rate of treatment failure; 3)
assessing the increase in resource utilization associated
with treatment failure; and 4) defining the risk factors for
treatment failure.
Methods
Study site
The study was conducted in a 700-bed tertiary care teach-
ing hospital, Brigham and Women's Hospital, Boston,
MA, and has approximately 35,000 admissions per year.
Patients were initially identified using the Brigham Inte-
grated Computer System (BICS), which stored patient
demographics (age, gender, race, insurance type, etc.) and
medication orders. The study was approved by the Part-
ners Human Research Committee.
Study population
The unit of analysis was the admission. All adult patients
admitted and discharged between 7/1/1997 and 6/30/
2001, who received oral or intravenous fluconazole were
eligible. Cancer patients with fever and neutropenia, and
who underwent empiric fluconazole antifungal therapy
were included in the final study cohort if they met all of
the following inclusion criteria: (1) an oncologic diagno-
sis; (2) an absolute neutrophil count (ANC) < 500 cells/
mm3  within 4 days prior to starting fluconazole; (3)
receiving at least 96 hours of parenteral systemic antibac-
terial therapy; (4) a fever (a temperature > 38°C or
100.4°F) within 4 days prior to start of fluconazole and
(5) no documented invasive fungal infections as the indi-
cation for initiation of fluconazole (based on the judg-
ment of the care providers as reported in the patients
medical record). The second and fourth criteria were
referred to any day within the 4 days prior to starting flu-
conazole. For patients with multiple courses of therapy
with fluconazole during the same admission, only those
who had neutropenia and fever prior to the first course of
fluconazole therapy were included in the final study
cohort.
Data
For patients eligible for the study, data were obtained
from both the BICS and the Transition Systems Incorpo-
rated (TSI; Boston, MA). For the final study cohort, addi-
tional data were collected through a chart review.
Demographic and other data including age, gender, race,
insurance status (classified as fee-for-service, health main-
tenance organization, Medicare, Medicaid and none),
course of therapy on fluconazole, type of hospital service,
primary diagnosis, discharge diagnosis-related group
(DRG) and laboratory results including neutrophil count,
bacterial and fungal cultures were collected from BICS.
Hospital costs were downloaded from the TSI system,
which uses a process costing technique to estimate the
expenses incurred by cost centers in providing products
and services.
In addition, charts were reviewed on the final study cohort
to collect additional information for a variety of variables.
These included the presence of major underlying diseases,
Charlson comorbidity score [14], the presence of organ
transplantation, date with fever, information about the
use of immunosuppressive therapy before empiric fluco-
nazole therapy, dosage and duration of fluconazole, and
presence of antifungal therapy before initiation and after
end of the empiric fluconazole therapy. Indications for
stopping the empiric fluconazole antifungal therapy were
classified as: positive fungal culture one day after starting
fluconazole up to the end of course without changing to
negative culture, persistent fever at the end of course with
negative bacterial and fungal cultures throughout the
course of fluconazole, ADE and/or toxicity due to flucona-
zole, patient death, care withdrawn and planned course of
fluconazole completed defined by fluconazole orders
having been completed and patients no longer having
fever and neutropenia. Information was also collected on
whether the patient was discharged on empiric flucona-
zole therapy or readmitted after being discharged.BMC Infectious Diseases 2006, 6:173 http://www.biomedcentral.com/1471-2334/6/173
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Outcome measures
The primary outcome was treatment failure, which was
considered present if any of the following criteria were
met: development or persistence of fungal infection evi-
denced by positive fungal culture during empiric flucona-
zole therapy and/or up to 7 days after fluconazole was
stopped, persistence of fever during empiric fluconazole
therapy and/or up to 7 days after fluconaozle therapy
without the presence of positive bacterial and fungal cul-
tures, ADE and/or toxicity due to fluconazole, and death
from any cause within 7 days after fluconazole was
stopped. Positive bacterial and fungal cultures were iden-
tified from laboratory reports of tests on specimens from
blood, bronchial alveolar lavage fluid, sputum, stool,
urine and catheter tips. The date of the laboratory report
was used to categorize patients with positive fungal cul-
tures before and after the initiation of empiric therapy.
The final study cohort included patients who had positive
fungal cultures reported before the initiation of flucona-
zole, but who did not meet the criteria for diagnosis of
invasive fungal infections (no patients had proven or
probable invasive fungal infection while one patient had
possible invasive fungal infection) as defined by the Euro-
pean Organization for Research and Treatment of Cancer
and the National Institute of Allergy and Infectious Dis-
eases Mycoses Study Group [1]. An ADE was defined as
"an injury resulting from an intervention related to a
drug" [15]. Length of stay (LOS) was measured in days
before and after empiric fluconazole antifungal therapy
was initiated. Total hospital costs were calculated using a
discount rate of 3% annually with the year 2001 as refer-
ence. In-hospital mortality was also measured.
Analyses
For each of the patient characteristics, dosage and dura-
tion of fluconazole, and outcomes of measurement,
counts with proportions, means with standard deviations,
and medians with ranges were determined as appropriate.
Univariate comparisons between admissions in which
treatment failure developed and those in which it did not
were made using the Wilcoxon rank-sum statistic for non-
normal continuous variables and the chi-square statistic
or Fisher's exact test for categorical variables. To identify
independent correlates of treatment failure, multivariate
analyses was performed using logistic regression. All vari-
ables prior to empiric fluconazole antifungal therapy were
included in the baseline model if they had an association
with the outcome with a P value less than 0.10 in the uni-
variate analysis. Stepwise logistic regression was used to
identify correlates of treatment failure, and variables were
retained using a threshold of P < 0.05. Multivariate com-
parisons were made using generalized linear modeling,
with length of stay and costs as the dependent variable
and treatment failure as the main covariate of interest,
adjusting for age, gender, insurance status, length of stay
before empiric fluconazole therapy, and DRG weight.
A sensitivity analysis was conducted using two
approaches. The first approach derived 95 percent confi-
dence intervals using bootstrap estimates (1,000 repeti-
tions) to develop a statistical range for the estimates of
total costs and length of stay. With the bootstrap method,
one can also determine the stability of the models' effect
estimates [16]. The second approach repeated resource
utilization models after excluding patients who had posi-
tive fungal cultures at baseline because these patients
might not be necessarily categorized as on empiric anti-
fungal therapy although none of them had proven inva-
sive fungal infections. Patients who had fungal infections
at baseline could have higher resource utilization than
others.
The final regression models to predict length of stay and
total costs were checked for outliers and influential points
[17]. Outliers were identified by examining the jackknife
residuals for all patients with studentized residuals greater
than 2 in absolute magnitude; six outliers were found. No
influential point was detected; the largest value of Cook's
distance was 0.18. We therefore present analyses without
excluding outliers. All analyses were performed using the
SAS statistical package [18].
Results
Among the total of 1,537 cancer patient admissions in
which fluconazole was administered orally and/or intra-
venously during their hospitalization in the four year
study period, 103 (6.7%, 95% CI 5.5% – 8.0%) were
treated with empiric fluconazole antifungal therapy for
neutropenia and fever after receiving at least 96 hours of
parenteral systemic antibacterial therapy. Among these
103 patient admissions, empiric antifungal treatment
failed in 42 (40.8%, 95% CI 31.3% – 50.3%) admissions
(Table 1). The most frequent causes of treatment failure
were positive fungal cultures (20 patients) and persistence
of fever with negative bacterial and fungal cultures (19
patients) during empiric fluconazole treatment or within
7 days after the end of empiric therapy. Other causes
included fluconazole-associated hepatotoxicity (n = 1)
and death earlier than 7 days after the end of empiric flu-
conazole therapy (n = 5). Three patients had multiple
causes of treatment failure. Among the 20 patients with
positive fungal cultures after the initiation of empiric ther-
apy, 7 had positive fungal cultures from the same type of
specimen prior to beginning empiric therapy.
ADE case report
One treatment failure was due to a serious ADE in a 28-
year-old woman with recurrent Hodgkin's disease who
had been admitted to the hospital for high dose chemo-BMC Infectious Diseases 2006, 6:173 http://www.biomedcentral.com/1471-2334/6/173
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therapy and bone marrow transplantation. Antifungal
treatment was started with intravenous fluconazole 200
mg daily on hospital day 9. On day 12, values of liver
function test were elevated (ALT = 147 IU/L, AST = 205
IU/L and BILT = 2.0 mg/dL). Fluconazole was discontin-
ued on day 13. The liver function results returned to a nor-
mal value on day 15 and remained normal until the day
of discharge. The patient did have chronic active hepatitis
B and was on lamivudine but the dose was unchanged
during the hospital course.
Characteristics
The final cancer patient cohort on empiric fluconazole
antifungal therapy (Table 2) had a mean age of 51 (+/- 14)
years, and was 60% female and 95% white. All patients
were receiving care from the oncology or bone marrow
transplant services prior to fluconazole treatment. Over
three quarters of the patients (76.7%) had hematological
malignancies including leukemia and myelodysplastic
syndrome (45.6%), lymphoma (22.3%), myeloma
(4.9%) and Hodgkin's disease (3.9%), while the remain-
der of the patients (23.3%) had solid tumors including
breast cancer (20.4%), endometrial cancer, neuroendo-
crine cancer and ovarian cancer. The vast majority of
patients (96.1%) were on immunosuppressive therapy
with steroids, cyclosporine or chemotherapy and more
than half had undergone bone marrow transplantation
before fluconazole treatment.
Among 98 patients on chemotherapy before fluconazole
was started, 37 patients were on chemotherapy for acute
leukemia, including 17 treated with induction chemo-
therapy and 20 on consolidation chemotherapy. A higher
prevalence of positive fungal cultures after initiation of
empiric fluconazole therapy was found among patient on
induction chemotherapy compared with those on consol-
idation chemotherapy (24% vs. 5%, P = 0.10).
Among 19 patients who had positive fungal cultures
before starting fluconazole therapy, isolates included C.
albicans (15) and yeast species not further identified (7)
from stool, urine and sputum specimen; 3 patients had
multiple positive fungal cultures from different types of
specimens. A total of 8 (7.8%) patients died in hospital
with higher prevalence in treatment failure group com-
pared with in non-treatment failure group (14% vs. 3%).
There were 5 patients in the treatment failure group who
died during empiric therapy or within 7 days after the end
of therapy, while 1 patient with and 2 patients without
treatment failure died after having been off treatment for
more than 7 days. Among those 5 dead in the treatment
failure group, 3 were died of sepsis or pneumonia.
Empiric antifungal therapy
In the 103 admissions (Table 3), all patients received
empiric fluconazole antifungal therapy for at least 4 days
(average 13.1 days) after admission to the hospital.
Among 5 patients on antifungal agent before empiric flu-
conazole therapy, all were on amphotericin for persistent
fever. Regarding fluconazole dosing, 85% (n = 87) were
given a maximum daily dosage of 100–200 mg. The mean
duration on empiric fluconazole therapy was 6.1 days.
The planned course of empiric fluconazole antifungal
therapy was completed in 41 (39.8%) admissions; fluco-
nazole was continued after discharge from the hospital in
11% of patients (n = 11). The therapy was discontinued in
50% of admissions (n = 51) (49.5%) admissions, because
of treatment failure (36), care withdrawal (1) and in other
cases without a specified reason (14). Among the 11
patients discharged on fluconazole, 9 patients were read-
mitted within 6 months after discharge, including 3
Table 1: Measure of Treatment Failure
Variable, No. (%) All
n = 103
Treatment failure 42 (40.8)
Reason for treatment failure *
Positive fungal cultures ** 20 (19.4)
During empiric fluconazole therapy 16 (15.5)
From day 1 to 7 after fluconazole stopped 6 (5.8)
Persistent fever with negative bacterial and fungal cultures † 19 (18.5)
During empiric fluconazole therapy 17 (16.5)
From day 1 to 7 after fluconazole stopped 4 (3.9)
ADE/toxicity due to fluconazole 1 (1.0)
Death within 7 days after fluconazole stopped 5 (4.9)
ADE, adverse drug event; * Three patients had multiple major reasons including 1 patient had positive fungal culture within 7 days after fluconazole 
stopped and persistent fever with negative bacterial and fungal cultures during empiric therapy, and 2 patients had persistent fever after initiation of 
fluconazole and died within 7 days after the end of fluconazole therapy; ** Positive fungal cultures referred to positive tests on specimen from 
blood, bronchial alverolar lavage, sputum, stool, urine and catheter tips and no report of negative results for repeated test on specimen from the 
same site, † fever present at least on the last day of fluconazole course and/or on day 7 after fluconazole stopped.BMC Infectious Diseases 2006, 6:173 http://www.biomedcentral.com/1471-2334/6/173
Page 5 of 10
(page number not for citation purposes)
patients with fever and neutropenia but no sufficient
information was present to determine whether they expe-
rienced fluconazole treatment failure while other 6
patients were readmitted for bone marrow transplant or
chemotherapy.
Correlates of treatment failure
Univariate correlates of treatment failure in variables
available prior to or during the course of fluconazole ther-
apy were diagnosis of hematological malignancies (P =
0.01) and Charlson score ≤ 4 (P = 0.01). In the multivari-
ate analysis, the only significant correlate of treatment
failure was a diagnosis of hematological malignancy
(Odds Ratio = 4.6, 95% CI, 1.5 to 14.8; Table 4).
Resource utilization of treatment failure
In crude analyses (Table 5), the mean length of stay (mean
± SE) for admissions in which treatment failure occurred
was 30.2 ± 1.9 days, versus 23.6 ± 1.5 days for admissions
without treatment failure, for a mean difference of 6.6
days (95% CI 1.9 – 11.3). For total costs, the mean differ-
ence was $15,888 (95% CI -493 – 32,270). We subse-
quently performed multiple regression analyses, adjusting
for potential confounders including age, gender, insur-
ance status, DRG weight and length of stay before initiat-
ing empiric fluconazole therapy. In these analyses, the
mean increase in length of stay associated with treatment
failure was 7.4 days (95% CI 3.3 – 11.5, P = 0.001). For
total costs, the mean adjusted increase associated with
Table 2: Patient Characteristics
All
(n = 103)
Treatment Failure
(n = 42)
No Treatment Failure
(n = 61)
Age, year, mean (SD) 51 (14.1) 51 (14.3) 51 (14.0)
Female, No. (%) 62 (60.2) 24 (57.1) 38 (62.3)
Nonwhite, No. (%) 5 (4.9) 4 (9.5) 1 (1.6)
Uninsured or Medicaid, No. (%) 12 (11.7) 6 (14.3) 6 (9.8)
Primary diagnosis, No. (%)
Hematological malignancies 79 (76.7) 38 (90.5) 41 (67.2) ‡
Acute leukemia/MDS 40 (38.8) 20 (47.6) 20 (32.8)
Chronic leukemia 7 (6.8) 3 (7.1) 4 (6.6)
Lymphoma 23 (22.3) 11 (26.2) 12 (19.7)
Myeloma 5 (4.9) 3 (7.1) 2 (3.3)
Hodgkin's disease 4 (3.9) 1 (2.4) 3 (4.9)
Solid tumors 24 (23.3) 4 (9.5) 20 (32.8)
Underlying disease, No. (%) 11 (10.7) 5 (11.9) 6 (9.8)
Cardiovascular disease 4 (3.9) 2 (4.8) 2 (3.3)
Others * 7 (6.8) 3 (7.1) 4 (6.6)
DRG weight, mean (SD) 7.4 (3.7) 7.0 (3.6) 7.7 (3.7)
Charlson score, mean (SD) 3.0 (1.7) 2.6 (1.4) 3.3 (1.8) ‡
Charlson score ≤ 4, No. (%) 80 (77.7) 38 (90.5) 42 (68.9) ‡
Treatment before fluconazole started, No. (%)
Steroid 17 (16.5) 7 (16.7) 10 (16.4)
Chemotherapy 98 (95.2) 38 (90.5) 60 (98.4)
Cyclosporin 6 (5.8) 3 (7.1) 3 (4.9)
History of Transplant, No. (%)
Bone marrow transplant 56 (54.4) 23 (54.7) 33 (54.1)
Lab results before fluconazole started, No. (%)
ANC ≤ 100/mm3 74 (71.8) 33 (78.6) 41 (67.2)
Positive fungal cultures ** 19 (18.5) 9 (21.4) 10 (16.4)
Candida albicans 15 (14.6) 8 (19.1) 7 (11.5)
Yeast species 7 (6.8) 3 (7.1) 4 (6.6)
Duration before fluconazole started, day, mean (SD)
Fever 7.9 (6.8) 7.5 (6.9) 8.3 (6.8)
Neutropenia 6.5 (6.9) 6.5 (6.8) 6.4 (7.0)
Deceased, No. (%) 8 (7.8) 6 (14.3) 2 (3.3) †
MDS, myelodysplastic syndrome; SD, standard deviation; DRG, diagnosis-related group; ANC, absolute neutrophil count;
* Other underlying diseases included chronic pulmonary disease, connective tissue disease, ulcer disease, mild liver disease, mild to moderate 
diabetes;
** Positive fungal cultures were reported for tests on specimen collected from sputum, stool and urine; three patients had multiple positive cultures 
from different type of specimen;
† 0.05 ≤ P < 0.10, ‡ 0.001 <P < 0.05 from Wilcoxon statistic, chi-square statistic or Fisher's exact test for comparision between non-failure and 
failure groups.BMC Infectious Diseases 2006, 6:173 http://www.biomedcentral.com/1471-2334/6/173
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treatment failure was $18,925 (95% CI 3,289 – 34,563, P
= 0.02).
After excluding 19 patients who had positive fungal cul-
tures at baseline, we repeated the above analyses compar-
ing the resource utilization between patients with and
without empiric antifungal treatment failure (33 vs. 51);
the adjusted mean increase in length of stay associated
with treatment failure was 8.1 days (95% CI 3.4 – 12.8, P
= 0.001), and the adjusted mean difference in costs was
$21,554 (95% CI 3,034 – 40,074, P = 0.03).
In the bootstrap validations, the adjusted mean total costs
associated with treatment failure was $18,780 (95% CI
2,515 – 35,044) and the adjusted mean increase in length
of stay associated with treatment failure was 7.4 days
(95% CI 3.1 – 11.7). We also evaluated the stability of the
parameter estimates for both models including all covari-
ates, and the parameter estimates and standard errors
were stable for all covariates (data not shown).
Discussion
In our study population, treatment failure occurred in
more than one-third of cancer patients receiving empiric
fluconazole antifungal therapy during an episode of
febrile neutropenia. This was usually manifested by devel-
opment and persistence of microbiologically documented
fungal infections or persistence of fever. Patients were at
higher risk if they had hematological malignancies. Treat-
ment failure was associated with substantially increased
length of stay and hospital costs, even after adjusting for
potential confounders.
The treatment failure rate found in the current study is in
the range of treatment failure or non-success rate (25%–
55%) in the fluconazole treatment arms from prospective
randomized trials comparing the efficacy of fluconazole
Table 3: Empiric Fluconazole Antifungal Therapy
Variable, No. (%) All
(n = 103)
Treatment Failure
(n = 42)
No Treatment Failure
(n = 61)
LOS before fluconazole started, day
Mean (SD) 13.1 (7.2) 12.7 (6.9) 13.4 (7.4)
Median (range) 12 (4–44) 11 (4–40) 12 (4–44)
On other systemic antifungal agent before fluconazole started
Amphotericin B 5 (4.9) 0 5 (8.2) †
Total fluconazole dosage, gm
Mean (SD) 1.2 (0.9) 1.0 (0.6) 1.2 (1.0)
Median (range) 1.0 (0.1–4.4) 0.9 (0.2–2.6) 1.0 (0.1–4.4)
Maximum fluconazole dosage per day, mg
Mean (SD) 218 (93) 229 (99) 211 (88)
100 – 150 mg 16 (15.5) 4 (9.5) 12 (19.7)
200 mg 71 (68.9) 31 (73.8) 40 (65.6)
400 – 600 mg 16 (15.5) 7 (16.7) 9 (14.8)
Duration on fluconazole, day
Mean (SD) 6.1 (4.8) 5.3 (3.5) 6.7 (5.4)
Median (range) 5 (1–24) 4 (1–19) 5 (1–24)
Therapy after stopping fluconazole
Amphotericin B 35 (34.0) 25 (59.5) 10 (16.4) ‡
Another azole angifungal agent 0
Empiric fluconazole therapy
Continued after discharged 11 (10.7) 0 11 (18.0) ‡
Stopped before discharged 92 (89.3) 42 (100%) 50 (82.0)
Indication for stopping fluconazole
Treatment failure 36 (35.0) 36 (85.7) 0 ‡
Positive fungal culture after starting fluconazole * 16 (15.5) 16 (38.1) 0 ‡
Persistent fever after starting fluconazole with negative bacterial and 
fungal cultures
17 (16.5) 17 (40.5) 0 ‡
ADE/toxicity due to fluconazole 1 (1.0) 1 (2.4) 0
Patient died 2 (1.9) 2 (4.8) 0
Planned course completed 41 (39.8) 1 (2.4) ** 40 (65.6) ‡
Care withdrawn/non-specified 15 (14.6) 5 (11.9) ** 10 (16.4)
LOS, length of hospital stay; SD, standard deviation; ADE, adverse drug event; * Positive fungal culture included fungal tests on specimen from 
blood, bronchial alverolar lavage, sputum, stool, urine and catheter tip; ** treatment failure determined as presence of positive fungal culture or 
persistent fever with negative bacterial and fungal cultures after stopping empiric fluconazole therapy up to 7 days; † 0.05 ≤ P < 0.10, ‡ 0.001 ≤ P < 
0.05 from Wilcoxon statistic, chi-square statistic or Fisher's exact test for comparision between non-failure and failure groups.BMC Infectious Diseases 2006, 6:173 http://www.biomedcentral.com/1471-2334/6/173
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and amphotericin B as empiric antifungal agents among
cancer patients with neutropenia and fever [10-13,19].
Generally, treatment response was measured similarly in
these studies, but there was variability in the length of
observation. In each previous trial, evaluation of response
was performed by primarily examining the change of fever
(with different cut-of-point from 37.6°C to 38.5°C) and
clinical or microbiological evidence of fungal infection,
development of adverse drug event or death resulting in
termination of antifungal medications. As noted above,
the follow-up period varied between trials; for example,
one trial observed patients response until 7 days after ini-
tiation of antifungal medication [10,12], while another
followed patients up to 21 days after the completion of
antifungal therapy [13]. In this study, we assessed for pres-
ence of fungal infection after initiation of empiric flucona-
zole therapy based on microbiological evidence, and
assessed the response to antifungal treatment during and
after the end of therapy for 7 days, which was also applied
in the most recent large trial [9] to evaluate the efficacy of
empiric antifungal therapy in patients with fever and neu-
tropenia.
Surviving for seven days was one of the criteria for success-
ful empiric antifungal treatment [8,9,20]; all deaths after
stopping antifungal therapy was classified as treatment
failure in previous trials [10,11] and in a recent forum
report issued by experts from multiple institutes [21]. This
was done because the exact cause of death is often difficult
to determine in this setting.
Our findings are partially consistent with previous trials
showing that the most frequent causes of treatment failure
were positive fungal cultures and persistence of fever,
while only persistence of fever was the major reason of
treatment failure in other trials [10,13]. The current study
included a broader range of patients than the clinical tri-
als, which could explain some of these differences. Among
7 patients who had positive fungal cultures prior to and
after the empiric therapy, the treatment failure for these
patients might be due to a low dose of fluconazole (6
patients on daily dose of 200 mg and 1 patient on 600
mg) while other trials on empiric fluconazole therapy
applied a daily dose of 400 mg [10-13,19]. Hepatotoxicity
was the major adverse event resulting in termination of
fluconaozle [19], though it was rare [11,13]. The variation
in mortality rates between studies may be due to differ-
ences in the severity of the underlying malignancies.
Several published studies have identified independent
factors for clinical outcomes in cancer patients who had
documented fungal infection [2,22,23]. or who received
empiric antifungal therapy [11]. In these reports, inde-
pendent correlates of death or persistent and break-
through fungal infection in cancer patients included
presence or persistence of neutropenia, increased severity
of illness, visceral dissemination, previous use of corticos-
teroids, absence of antifungal treatment, older age and
low performance status [2,22,23]. A trial comparing fluco-
nazole and amphotericin B as empiric antifungal agents in
cancer patients with prolonged fever and neutropenia
Table 5: Resource Utilization among Cancer Patients with Empiric Fluconazole Antifungal Therapy by Treatment Failure
Treatment Failure No Treatment Failure Difference PR 2
N4 2 6 1
LOS, day
Unadjusted Mean (SE) 30.3 (1.9) 23.7 (1.5) 6.6 0.007
Median (range) 27 (8–73) 22 (4–55) 5.0
Adjusted Mean (SE) * 30.7 (1.6) 23.4 (1.3) 7.3 0.001 0.34
Total Costs per patient, $
Unadjusted Mean (SE) 71,122 (6,432) 55,234 (5,337) 15,888 0.060
Median (range) 56,924 (10,647–275,130) 47,642 (3,416–268,447) 9,282
Adjusted Mean (SE) * 72,921 (6,118) 53,996 (5,068) 18,925 0.020 0.18
LOS, length of stay; SE, standard error;
* Adjusted for age, gender, insurance status (uninsured or Medicaid), DRG weight and length of stay before empiric fluconazole therapy.
Table 4: Odds Ratios for Predictors of Treatment Failure
Predictors Odds Ratios (95% CI) p
Hematological malignancies * 4.63 (1.45 – 14.79) 0.01
Charlson score ≤ 4 4.30 (1.34 – 13.76) 0.01
CI, confidence interval;
* The only independent predictor remained in the final logistic regression model using stepwise selection procedure, while the baseline model 
including hematological malignancies, Charlson score ≤ 4BMC Infectious Diseases 2006, 6:173 http://www.biomedcentral.com/1471-2334/6/173
Page 8 of 10
(page number not for citation purposes)
examined the correlates of treatment failure and found
that persistence of neutropenia and pneumonia were
independent predictors [11]. However, in the current
study, which included only oncology and bone marrow
transplantation patients, patient age, duration of neutro-
penia and immunosuppressive therapy before initiation
of fluconazole were not correlated with treatment failure.
There was a univariate relationship between lower Charl-
son comorbidity score and treatment failure but this vari-
able was not retained in the stepwise multivariate model.
In the current study, we found that treatment failure had
a significant economic impact. Other recent studies have
confirmed findings from earlier reports which demon-
strated excess resource utilization attributable to fungal
infections [24-30]. It might have been expected that
patients with hematological malignancy would have
longer duration of neutropenia and hospital stays result-
ing in higher treatment failure rates compared to patients
with solid tumors. However, the economic costs associ-
ated with fungal infections and antifungal treatment in
cancer patients have seldom been assessed, and in partic-
ular limited data are available from routine care. One
study used data from cancer registries and Medicare
claims to evaluate the resource utilization associated with
fungal infections among hospitalized cancer patients and
found that cancer patients with fungal infections had
longer length of stay (10–11 days) and higher costs
($10,479–$15,966 in Medicare expenditures) compared
with same age group of cancer patients without fungal
infections [27]. The study by Menzin et al. also found that
isolates of Candida species were the most common type of
fungal infections. Similar findings on the baseline isolates
were also found in the current study. However, neither
details about antifungal medications nor the clinical
response to antifungal treatment was reported by Menzin
[27]. Another multicenter trial compared the hospital
costs and length of stay between febrile neutropenic can-
cer patients on empiric therapy with liposomal and con-
ventional amphotericin B, and found the mean total
hospital costs to be $77,496 versus $82,075, and length of
stay of 32.1 versus 32.5 days, respectively, although no
data on treatment failure were reported [31].
Many clinicians believe that any cancer patient with per-
sistent fever and profound neutropenia after 5 days of
adequate doses of broad-spectrum antibiotics is a candi-
date for antifungal therapy [7]. Amphotericin B has been
used as empiric antifungal agent for many years since the
early efficacy data were published in 1980s [4,5]. How-
ever, serious toxicities associated with amphotericin B led
to more randomized trials on empiric antifungal therapy
using other agents including three lipid formulations of
amphotericin B [20,32-34], azoles (fluconazole [10-
13,35], itraconazole [36] and voriconazole [8]) and echi-
nocandins (caspofungin [9]). The choice of agents for
empiric antifungal therapy is not clear due to the similar-
ity of clinical effectiveness found from above comparative
trials, while decisions on specific antifungal drug use
depends on multiple factors, including risk of infection
caused by specific fungal pathogen, spectrum of activity,
toxicity of drug, patient's tolerability to drug and treat-
ment related costs [7,37-39].
The current study has several limitations. We used a retro-
spective design and relied on documentation in patient
charts to identify clinically significant adverse events
attributable to fluconazole. As a result, we may have
missed undocumented adverse effects. The number of
patients included in the final analysis may have been too
small to identify some correlates of treatment failure.
Finally, this study was performed in the inpatient setting
at one tertiary care hospital, so the results may not be gen-
eralizable to other institutions or settings.
Conclusion
The incidence of treatment failure associated with empiric
fluconazole antifungal therapy is high among cancer
patients, particularly in those suffering from hematologi-
cal malignancies, and that the additional length of stay
and hospital costs associated with treatment failure are
high. These data suggest that alternative agents that reduce
frequency of treatment failure may be cost-effective. Fur-
thermore, additional evaluation to assess the frequency of
treatment failure and its associated resource utilization
should be carried out for other agents that are used for
empiric antifungal therapy.
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